edoc

A comparative study of CSF neurofilament light and heavy chain protein in MS

Kuhle, J. and Plattner, K. and Bestwick, J. P. and Lindberg, R. L. and Ramagopalan, S. V. and Norgren, N. and Nissim, A. and Malaspina, A. and Leppert, D. and Giovannoni, G. and Kappos, L.. (2013) A comparative study of CSF neurofilament light and heavy chain protein in MS. Multiple Sclerosis Journal, 19 (12). pp. 1597-1603.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6338331

Downloads: Statistics Overview

Abstract

BACKGROUND: There is a lack of reliable biomarkers of axonal degeneration. Neurofilaments are promising candidates to fulfil this task. We compared two highly sensitive assays to measure two subunits of the neurofilament protein (neurofilament light (NfL) and neurofilament heavy chain (NfH)). METHODS: We evaluated the analytical and clinical performance of the UmanDiagnostics NF-light((R)) enzyme-linked immunosorbent assay (ELISA) in the cerebrospinal fluid (CSF) of a group of 148 patients with clinically isolated syndrome (CIS) or multiple sclerosis (MS), and 72 controls. We compared our results with referring levels of our previously-developed CSF NfH(SMI35) assay. RESULTS: Exposure to room temperature (up to 8 days) or repetitive thawing (up to 4 thaws) did not influence measurement of NfL concentrations. Values of NfL were higher in all disease stages of CIS/MS, in comparison to controls (p >/= 0.001). NfL levels correlated with the Expanded Disability Status Scale (EDSS) score in patients with relapsing disease (r(s) = 0.31; p = 0.002), spinal cord relapses and with CSF markers of acute inflammation. The ability of NfL to distinguish patients from controls was greater than that of NfH(SMI35) in both CIS patients (p = 0.001) and all MS stages grouped together (p = 0.035). CONCLUSIONS: NfL proved to be a stable protein, an important prerequisite for a reliable biomarker, and the NF-light((R)) ELISA performed better in discriminating patients from controls, compared with the ECL-NfH(SMI35) immunoassay. We confirmed and expanded upon previous findings regarding neurofilaments as quantitative markers of neurodegeneration. Our results further support the role of neurofilaments as a potential surrogate measure for neuroprotective treatment in MS studies.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Clinical Neuroimmunology (Derfuss/Lindberg)
UniBasel Contributors:Lindberg Gasser, Raija L.P. and Kappos, Ludwig
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:SAGE
ISSN:1352-4585
e-ISSN:1477-0970
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:02 Nov 2017 13:44
Deposited On:10 Apr 2015 09:12

Repository Staff Only: item control page